The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
News|Articles|September 2, 2005
- Pharmaceutical Technology-09-02-2005
- Volume 29
- Issue 9
Applications of Poly(ethylene in Drug Delivery Systems: Part II
Poly(ethylene oxide) is gaining the attention of research and development organizations and its application is extending into a wide range of drug delivery systems.
Advertisement
Articles in this issue
about 21 years ago
Securing the Supply Chain With RFIDabout 21 years ago
Analytical Method Equivalency: An Acceptable Analytical Practiceabout 21 years ago
September 2005about 21 years ago
Pilots and Partnerships Move RFID Forwardabout 21 years ago
Reshaping CMC Development Servicesabout 21 years ago
Wash. Rinse. Repeatabout 21 years ago
Outsourcing Atrophy: A Cautionary Taleabout 21 years ago
In the Spotlight-September 2005Advertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Advertisement
Advertisement